TrialEBioMedicine2022

Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial.

Frédéric Vanhoutte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.